Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration
Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/
Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)
juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3
Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:
- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4
- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.
- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity.5
Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:
- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars
- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars
Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.
juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.
"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.
1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier
2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
3 available with CE 0373
4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.
PRJ0821
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005466/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Red Sea Global Unveils Shura Island: A New Era of Luxury Tourism Begins This September15.9.2025 14:30:00 EEST | Press release
Red Sea Global (RSG), the developer behind regenerative tourism destinations The Red Sea and AMAALA, has announced that the first resorts and attractions on Shura Island will begin opening to guests in the coming weeks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915221123/en/ The EDITION Red Sea, opening soon on Shura Island features 240 elegantly designed rooms and suites. Phase one of the launch includes the debut of SLS, EDITION, and InterContinental hotels, along with Shura Links, Saudi Arabia’s first island golf course. This moment marks a major milestone for RSG as it continues making Vision 2030’s ambitions for national transformation and economic diversification a reality for the people of Saudi Arabia, as well as demonstrating the possibility of regenerative tourism. “As the heart of The Red Sea, Shura Island represents everything Red Sea Global stands for: bold ambition, deep respect for nature, and a commit
Signifyd Launches Intelligent Returns to Help Retailers Tackle the Growing Returns Challenge15.9.2025 14:14:00 EEST | Press release
Commerce protection provider Signifyd today unveiled Intelligent Returns, a two-solution suite designed to help retailers in the UK and Europe tackle the growing complexity and cost of returns. Consumers are clear about what they expect from retailers and in the UK and EU with consumer rights legislation reinforcing those expectations. A Signifyd survey of thousands of shoppers across the UK, Spain, Italy and France found that 77 percent say return policies strongly influence where they shop, while 94 percent say ease of return is essential. Legal protections, however, often leave retailers with limited flexibility to adjust their policies, making it harder to control costs and abuse without risking customer loyalty. This is especially challenging when fewer than half of consumers say they would buy from a retailer that only offers store credit or charges for returns. Signifyd’s Intelligent Returns addresses this challenge with two new solutions. Instant Refunds provides retailers with
Cessna Citation Ascend Program Continues to Advance With Rollout of First Production Unit15.9.2025 14:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced its Cessna Citation Ascend business jet program continues to advance as the first production unit rolled out of the manufacturing facility in Wichita, Kansas. The aircraft is expected to achieve certification from the Federal Aviation Administration later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915961668/en/ Cessna Citation Ascend program continues to advance with rollout of first production unit (Photo credit: Textron Aviation). Employees held a special celebration to mark the major program milestone of the newest Citation business jet in the legendary 560XL series as they continue to design and deliver the best aviation experience for customers. “Today is a big celebration and thank you to everyone who has been a part of building up to this point. It is your craftsmanship that continues to make milestones like this possible,” sai
Trade Republic expands from Brokerage to Wealth Management – Invest into Private Markets from 1 euro. Start of strategic partnership with Apollo and EQT.15.9.2025 13:41:00 EEST | Press release
Trade Republic, Europe's largest savings platform, continues to grow, surpassing 10 million customers, across 18 European markets and more than 150 billion euro in assets under management. Through strategic partnerships with Apollo and EQT, Trade Republic expands its services to offer access to Private Markets. In the coming months, the bank will roll out two additional asset classes, each 30 days apart. "Long-term wealth creation is more than just an ETF savings plan. It's about the combination of various asset classes. Now, we are growing Trade Republic from brokerage into wealth management," says Christian Hecker, Co-Founder of Trade Republic. "Everyone in Europe shall have the opportunity to invest like the very wealthy — simple, secure, and at the lowest possible cost. Following our expansion into banking, with checking accounts and cards, this is the most significant milestone since our founding. With Apollo and EQT, we have secured two of the most important Private Markets manag
Jumpmind Announces Strategic Investment from Lone View Capital15.9.2025 13:00:00 EEST | Press release
Jumpmind, a leading provider of innovative retail technology solutions, announced today that Lone View Capital (“Lone View”), a growth-oriented private equity firm focused on technology and software investments, has made a strategic investment, acquiring a controlling stake in the company. Founded in 2008, Jumpmind was recently recognized as a Leader in the Forrester Wave™ for Point of Service Solutions (Q4 2024). The company’s flagship product, Jumpmind Commerce, is a cloud-native, microservices-based point of service platform that enables retailers to unify digital and in-store experiences, streamline checkout, and deliver more personalized customer interactions. Trusted by leading retailers worldwide, the platform supports device independence, rapid deployment, and highly configurable customer journeys – empowering enterprises to adapt quickly in today’s dynamic retail landscape. Jumpmind was named POS Solution of the Year in the 2025 RetailTech Breakthrough Awards. In addition to i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom